zotepine has been researched along with Dementia Praecox in 76 studies
zotepine: structure
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine is the most effective antipsychotic for patients with treatment-refractory schizophrenia, but many adverse effects are noted." | 9.17 | Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study. ( Bai, YM; Chen, JY; Chen, TT; Chiu, HJ; Lin, CC; Liou, YJ; Wang, YC, 2013) |
| "Patients with acute exacerbation of schizophrenia (DSM-III-R criteria; n = 158) were allocated on a random, double-blind basis to receive zotepine (150 or 300 mg/day), chlorpromazine (300 or 600 mg/day) or placebo for 8 weeks." | 9.09 | A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. ( Butler, A; Cooper, SJ; Raniwalla, J; Tweed, J; Welch, C, 2000) |
| "Zotepine is effective in preventing recurrence in patients with chronic schizophrenia." | 9.09 | Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. ( Butler, A; Cooper, SJ; Raniwalla, J; Tweed, J; Welch, C, 2000) |
| "The atypical antipsychotic zotepine was compared to haloperidol in 126 patients suffering from acute exacerbation of schizophrenia (DSM-III-R) in a randomized, double-blind study." | 9.08 | A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. ( Dollfus, S; Kelly, F; Leutenegger, E; Petit, M; Raniwalla, J; Tweed, J, 1996) |
| "Zotepine was administered to 45 patients suffering from therapy-resistant psychoses hospitalized in eight psychiatric institutes (University Hospital Okayama and affiliated institutions)." | 9.07 | [Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics]. ( Fujiwara, Y; Harada, T; Otsuki, S, 1991) |
| "To evaluate the effects of zotepine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychoses." | 8.86 | Zotepine versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "To compare the clinical effects of clozapine with other atypical antipsychotics (such as amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) in the treatment of schizophrenia and schizophrenia-like psychoses." | 8.86 | Clozapine versus other atypical antipsychotics for schizophrenia. ( Asenjo Lobos, C; Hunger, H; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "This paper incorporates data on placebo-controlled studies of zotepine as well as studies with comparator compounds also beyond the diagnostic boarder of schizophrenia regarding zotepine's safety." | 8.86 | Safety evaluation of zotepine for the treatment of schizophrenia. ( Möller, HJ; Musil, R; Riedel, M; Schennach-Wolff, R; Seemüller, F; Spellmann, I, 2010) |
| "We included only randomised clinical controlled trials that compared zotepine with any forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole or ziprasidone in people suffering from only schizophrenia or schizophrenia-like psychoses." | 8.86 | Zotepine versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Subramanian, S, 2010) |
| "To determine the effects of zotepine compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses." | 8.83 | Zotepine for schizophrenia. ( DeSilva, P; Fenton, M; Rathbone, J, 2006) |
| "All randomised clinical trials that compared zotepine to other treatments for people with schizophrenia or other psychoses were included." | 8.80 | Zotepine for schizophrenia. ( Bagnall, A; Cooper, SJ; De-Silva, P; Fenton, M; Gammelin, G; Leitner, M; Morris, S, 2000) |
| "135 acutely ill inpatients with DSM-IV-defined schizophrenia received 4 weeks of 150 mg/day zotepine treatment." | 7.74 | Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. ( Chen, YS; Chou, LS; Hsu, CY; Lane, HY; Lin, CH, 2007) |
| "The purpose of the present paper was to remind physicians that hypothermia is a possible side-effect of combining zotepine, valproate,and benzodiazepine." | 7.72 | Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. ( Chen, KC; Chen, PS; Yang, MJ; Yang, YK; Yeh, TL, 2003) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 7.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "One hundred twenty-nine schizophrenic inpatients who were administered zotepine were studied to see if they had zotepine-induced convulsive seizures." | 7.68 | Convulsive seizures in schizophrenic patients induced by zotepine administration. ( Hori, M; Koizumi, J; Sasaki, M; Shiraishi, H; Suzuki, T, 1992) |
| "In the presented case a hyperlipidemia (triglycerides up to 1247 mg/dl) was observed soon after the beginning of zotepine medication." | 5.31 | [Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?]. ( Wetterling, T, 2002) |
| "Zotepine is a new tricyclic neuroleptic with a pharmacological profile comparable to substances like Thioridazine and Chlorpromazine." | 5.27 | Zotepine in the treatment of negative symptoms in chronic schizophrenia. ( Barnas, C; Fleischhacker, WW; Hinterhuber, H; Stuppäck, C; Unterweger, B, 1987) |
| "Clozapine is the most effective antipsychotic for patients with treatment-refractory schizophrenia, but many adverse effects are noted." | 5.17 | Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study. ( Bai, YM; Chen, JY; Chen, TT; Chiu, HJ; Lin, CC; Liou, YJ; Wang, YC, 2013) |
| "Zotepine is effective in preventing recurrence in patients with chronic schizophrenia." | 5.09 | Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. ( Butler, A; Cooper, SJ; Raniwalla, J; Tweed, J; Welch, C, 2000) |
| "Patients with acute exacerbation of schizophrenia (DSM-III-R criteria; n = 158) were allocated on a random, double-blind basis to receive zotepine (150 or 300 mg/day), chlorpromazine (300 or 600 mg/day) or placebo for 8 weeks." | 5.09 | A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. ( Butler, A; Cooper, SJ; Raniwalla, J; Tweed, J; Welch, C, 2000) |
| " The purpose of this study was to compare the efficacy and safety of zotepine and haloperidol in Taiwanese patients with schizophrenia." | 5.09 | Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. ( Hwang, TJ; Lin, HN; Lin, SK, 2001) |
| "The atypical antipsychotic zotepine was compared to haloperidol in 126 patients suffering from acute exacerbation of schizophrenia (DSM-III-R) in a randomized, double-blind study." | 5.08 | A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. ( Dollfus, S; Kelly, F; Leutenegger, E; Petit, M; Raniwalla, J; Tweed, J, 1996) |
| "40 inpatients suffering from a schizophrenia (ICD-9) were treated with either zotepine or perazin." | 5.07 | [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients]. ( Ackenheil, M; Dieterle, DM; Müller-Spahn, F, 1991) |
| "Zotepine was administered to 45 patients suffering from therapy-resistant psychoses hospitalized in eight psychiatric institutes (University Hospital Okayama and affiliated institutions)." | 5.07 | [Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics]. ( Fujiwara, Y; Harada, T; Otsuki, S, 1991) |
| "To evaluate the effects of zotepine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychoses." | 4.86 | Zotepine versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "This paper incorporates data on placebo-controlled studies of zotepine as well as studies with comparator compounds also beyond the diagnostic boarder of schizophrenia regarding zotepine's safety." | 4.86 | Safety evaluation of zotepine for the treatment of schizophrenia. ( Möller, HJ; Musil, R; Riedel, M; Schennach-Wolff, R; Seemüller, F; Spellmann, I, 2010) |
| "To compare the clinical effects of clozapine with other atypical antipsychotics (such as amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) in the treatment of schizophrenia and schizophrenia-like psychoses." | 4.86 | Clozapine versus other atypical antipsychotics for schizophrenia. ( Asenjo Lobos, C; Hunger, H; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| "We included only randomised clinical controlled trials that compared zotepine with any forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole or ziprasidone in people suffering from only schizophrenia or schizophrenia-like psychoses." | 4.86 | Zotepine versus other atypical antipsychotics for schizophrenia. ( Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S; Subramanian, S, 2010) |
| "To determine the effects of zotepine compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses." | 4.83 | Zotepine for schizophrenia. ( DeSilva, P; Fenton, M; Rathbone, J, 2006) |
| "All randomised clinical trials that compared zotepine to other treatments for people with schizophrenia or other psychoses were included." | 4.80 | Zotepine for schizophrenia. ( Bagnall, A; Cooper, SJ; De-Silva, P; Fenton, M; Gammelin, G; Leitner, M; Morris, S, 2000) |
| "A man with schizophrenia received regular haloperidol ester therapy, but his psychotic symptoms were not mitigated." | 3.74 | Zotepine-induced spontaneous ejaculation. ( Huang, CJ; Wang, PW; Wang, SY, 2008) |
| "135 acutely ill inpatients with DSM-IV-defined schizophrenia received 4 weeks of 150 mg/day zotepine treatment." | 3.74 | Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. ( Chen, YS; Chou, LS; Hsu, CY; Lane, HY; Lin, CH, 2007) |
| "The purpose of the present paper was to remind physicians that hypothermia is a possible side-effect of combining zotepine, valproate,and benzodiazepine." | 3.72 | Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy. ( Chen, KC; Chen, PS; Yang, MJ; Yang, YK; Yeh, TL, 2003) |
| "During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain." | 3.70 | Weight gain: side effect of atypical neuroleptics? ( Müssigbrodt, HE; Wetterling, T, 1999) |
| "During our clinical experience with the new neuroleptic drug zotepine we saw some cases of marked weight gain." | 3.69 | [Body weight increase: a side effect of zotepin (Nipolept)?]. ( Müssigbrodt, H; Wetterling, T, 1996) |
| "One hundred twenty-nine schizophrenic inpatients who were administered zotepine were studied to see if they had zotepine-induced convulsive seizures." | 3.68 | Convulsive seizures in schizophrenic patients induced by zotepine administration. ( Hori, M; Koizumi, J; Sasaki, M; Shiraishi, H; Suzuki, T, 1992) |
| "One schizophrenic and two manic-depressive patients who after the administration of zotepine, a new antipsychotic and antimanic drug, developed alopecia areata, a kind of autoimmune disease, are reported." | 3.68 | Three cases of alopecia areata induced by zotepine. ( Ishikura, T; Jibiki, I; Kubota, T, 1993) |
| "Zotepine, a new neuroleptic, was administered to 23 hospitalized patients with schizophrenia at doses of 75 to 600 mg/d for 21 to 42 days." | 3.67 | Clinical and neuroendocrine effects of zotepine--a new neuroleptic drug. ( Benkert, O; Holsboer, F; von Bardeleben, U, 1987) |
| "We reported the results of a survey of patients who suffered from schizophrenia with predominate hallucinatory and delusional states, and who had been unresponsive to a variety of antipsychotics like haloperidol but responded more favorably to zotepine." | 3.67 | Effectivity of zotepine in refractory psychoses: possible relationship between zotepine and non-dopamine psychosis. ( Fujiwara, Y; Fukuda, K; Harada, T; Kashihara, K; Otsuki, S; Sato, M; Wake, A, 1987) |
| "In a schizophrenic patient, hypothermia was caused by combined treatment with zotepine, biperiden, and fluphenazine, although combined treatment with zotepine and biperiden had caused no side effects." | 3.67 | Hypothermia caused by antipsychotic drugs in a schizophrenic patient. ( Hashimoto, H; Kamimura, H; Nakajima, T; Nakao, J; Noto, T; Okamoto, K; Sugae, S, 1987) |
| "This was a 6-week, multicenter, randomized, open-label, parallel-group, flexible dosing study." | 2.78 | An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. ( Chan, HY; Chen, KP; Chen, YY; Cheng, JS; Lin, AS; Tsai, CJ, 2013) |
| "The much lower prevalence of hyperprolactinaemia over 2 000 mIU/l differentiates olanzapine from amisulpride and risperidone." | 2.73 | Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. ( Cejpková, A; Rodáková, I; Svestka, J; Synek, O; Tomanová, J, 2007) |
| "Zotepine was not superior to placebo in reducing the severity of stable primary negative symptoms in schizophrenic patients in this trial." | 2.71 | Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. ( Fischer, W; Kohnen, R; Möller, HJ; Müller, N; Riedel, M, 2004) |
| "Zotepine and clozapine were equally effective." | 2.68 | Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. ( Bauer, U; Gallhofer, B; Gruppe, H; Krieger, S; Lis, S; Meyer-Lindenberg, A, 1997) |
| "Zotepine, a new tricyclic compound, was investigated in 20 schizophrenic patients in two different dosage groups." | 2.66 | Zotepine, a neuroleptic drug with a bipolar therapeutic profile. ( Ackenheil, M; Dieterle, DM; Kapfhammer, HP; Müller-Spahn, F, 1987) |
| "Zotepine is a second generation antipsychotic drug, a substituted dibenzothiepine tricyclic molecule, with effects on dopamine, serotonin and noradrenaline receptors." | 2.45 | Zotepine: a clinical review. ( Green, B, 2009) |
| " Published studies have drawn criticism in terms of inappropriate titration schedules, nonequivalent dosing between treatment groups, short treatment duration, and inadequate sample sizes." | 2.40 | Clozapine: a comparison with other novel antipsychotics. ( Fleischhacker, WW, 1999) |
| "In the presented case a hyperlipidemia (triglycerides up to 1247 mg/dl) was observed soon after the beginning of zotepine medication." | 1.31 | [Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?]. ( Wetterling, T, 2002) |
| " Within the dosage range of 50-450 mg (mean at the end of the study, 207 +/- 125 mg/day), a significant reduction of positive as well as negative symptoms was noted." | 1.31 | Zotepine in the treatment of acute hospitalized schizophrenic episodes. ( Barnas, C; Fabisch, H; Haushofer, M; Kasper, S; König, P; Lingg, A; Platz, T; Quiner, S; Rittmannsberger, H; Sackel, C; Stuppäck, C; Willeit, M; Zapotoczky, HG, 2001) |
| " Adverse effects were evaluated by the UKU Side Effect Rating Scale (21 items)." | 1.29 | Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. ( Fukushima, Y; Ishida, M; Kaneko, S; Kondo, T; Otani, K; Tanaka, O, 1994) |
| "The spectrum of therapeutic and adverse effects of zotepine and their relationships with serum concentrations of the drug were investigated in 28 schizophrenic inpatients by a fixed-dose (100 mg/day for the first 1 wk and 200 mg/day for the following 3 wk) study." | 1.29 | [Therapeutic and adverse effects of zotepine and their relationships with serum kinetics of the drug]. ( Ishida, M, 1993) |
| "Zotepine is a new tricyclic neuroleptic with a pharmacological profile comparable to substances like Thioridazine and Chlorpromazine." | 1.27 | Zotepine in the treatment of negative symptoms in chronic schizophrenia. ( Barnas, C; Fleischhacker, WW; Hinterhuber, H; Stuppäck, C; Unterweger, B, 1987) |
| "Zotepine is a new tricyclic neuroleptic with a pharmacological profile comparable to substances such as thioridazine and chlorpromazine." | 1.27 | Results of an open phase II study with zotepine--a new neuroleptic compound. ( Barnas, C; Fleischhacker, WW; Hinterhuber, H; Stuppäck, C; Unterweger, B, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (17.11) | 18.7374 |
| 1990's | 20 (26.32) | 18.2507 |
| 2000's | 26 (34.21) | 29.6817 |
| 2010's | 15 (19.74) | 24.3611 |
| 2020's | 2 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Rowley, M | 1 |
| Bristow, LJ | 1 |
| Hutson, PH | 1 |
| Ishikawa, S | 1 |
| Yamamura, R | 1 |
| Hashimoto, N | 1 |
| Okubo, R | 1 |
| Sawagashira, R | 1 |
| Ito, YM | 1 |
| Sato, N | 1 |
| Kusumi, I | 1 |
| Chen, PH | 1 |
| Tsai, SY | 2 |
| Pan, CH | 1 |
| Chang, CK | 1 |
| Su, SS | 1 |
| Chen, CC | 3 |
| Kuo, CJ | 2 |
| Lin, CC | 2 |
| Chiu, HJ | 1 |
| Chen, JY | 2 |
| Liou, YJ | 2 |
| Wang, YC | 2 |
| Chen, TT | 1 |
| Bai, YM | 2 |
| Chan, HY | 1 |
| Lin, AS | 1 |
| Chen, KP | 1 |
| Cheng, JS | 1 |
| Chen, YY | 1 |
| Tsai, CJ | 1 |
| Ling, MW | 1 |
| Liu, YW | 1 |
| Huang, RH | 1 |
| Liang, CS | 1 |
| Chen, TR | 1 |
| Chen, YC | 1 |
| Ouyang, WC | 1 |
| Wang, PW | 1 |
| Wang, SY | 1 |
| Huang, CJ | 1 |
| Green, B | 1 |
| Komossa, K | 3 |
| Rummel-Kluge, C | 3 |
| Hunger, H | 3 |
| Schmid, F | 3 |
| Schwarz, S | 3 |
| Kissling, W | 2 |
| Leucht, S | 3 |
| Riedel, M | 2 |
| Musil, R | 1 |
| Seemüller, F | 1 |
| Spellmann, I | 1 |
| Möller, HJ | 3 |
| Schennach-Wolff, R | 1 |
| Subramanian, S | 1 |
| Asenjo Lobos, C | 1 |
| Hsu, WY | 1 |
| Kuo, SY | 1 |
| Huang, SS | 1 |
| Chang, TG | 1 |
| Chiu, NY | 1 |
| Yang, SY | 1 |
| Liao, YT | 1 |
| Chen, WJ | 1 |
| Lee, WC | 1 |
| Shau, WY | 1 |
| Chang, YT | 1 |
| Suzuki, Y | 1 |
| Watanabe, J | 1 |
| Sugai, T | 1 |
| Fukui, N | 1 |
| Ono, S | 1 |
| Tsuneyama, N | 1 |
| Saito, M | 1 |
| Someya, T | 1 |
| Huang, WL | 1 |
| Chang, LR | 1 |
| Chen, IM | 1 |
| Hsieh, MH | 1 |
| Hwang, TJ | 2 |
| Liu, CC | 1 |
| Pai, MS | 1 |
| Yang, SN | 1 |
| Shiah, IS | 1 |
| Lin, CH | 4 |
| Chou, LS | 2 |
| Hsu, CY | 2 |
| Lane, HY | 2 |
| Briken, P | 1 |
| Nika, E | 1 |
| Moritz, S | 1 |
| Haasen, C | 1 |
| Perro, C | 1 |
| Yagdiran, O | 1 |
| Naber, D | 2 |
| Krausz, M | 1 |
| Wetterling, T | 3 |
| Chen, KC | 1 |
| Yang, YK | 1 |
| Chen, PS | 1 |
| Yeh, TL | 1 |
| Yang, MJ | 1 |
| Müller, N | 1 |
| Fischer, W | 1 |
| Kohnen, R | 1 |
| Nadeem, Z | 2 |
| McIntosh, A | 2 |
| Lawrie, S | 2 |
| Hashimoto, K | 1 |
| Sudo, T | 1 |
| Hirano, M | 1 |
| Motomura, H | 1 |
| Tagawa, K | 1 |
| Nashiro, S | 1 |
| Uemura, K | 1 |
| Yoshimoto, S | 1 |
| DeSilva, P | 1 |
| Fenton, M | 2 |
| Rathbone, J | 1 |
| Chen, YS | 1 |
| Svestka, J | 1 |
| Synek, O | 1 |
| Tomanová, J | 1 |
| Rodáková, I | 1 |
| Cejpková, A | 1 |
| Otani, K | 3 |
| Kondo, T | 3 |
| Kaneko, S | 3 |
| Ishida, M | 3 |
| Fukushima, Y | 3 |
| Kubota, T | 1 |
| Ishikura, T | 1 |
| Jibiki, I | 1 |
| Tanaka, O | 1 |
| Müssigbrodt, H | 1 |
| Petit, M | 1 |
| Raniwalla, J | 3 |
| Tweed, J | 3 |
| Leutenegger, E | 1 |
| Dollfus, S | 1 |
| Kelly, F | 1 |
| Meyer-Lindenberg, A | 1 |
| Gruppe, H | 1 |
| Bauer, U | 1 |
| Lis, S | 2 |
| Krieger, S | 1 |
| Gallhofer, B | 2 |
| Franz, M | 1 |
| Plüddemann, K | 1 |
| Tokunaga, H | 1 |
| Kudo, K | 1 |
| Imamura, T | 1 |
| Jitsufuchi, N | 1 |
| Ohtsuka, Y | 1 |
| Ikeda, N | 1 |
| Fleischhacker, WW | 8 |
| Müssigbrodt, HE | 1 |
| Lavori, PW | 1 |
| Sugarman, J | 1 |
| Cooper, SJ | 3 |
| Butler, A | 2 |
| Welch, C | 2 |
| Morris, S | 1 |
| De-Silva, P | 1 |
| Bagnall, A | 1 |
| Gammelin, G | 1 |
| Leitner, M | 1 |
| Kapur, S | 1 |
| Remington, G | 1 |
| Hilger, E | 2 |
| Kasper, S | 3 |
| Quiner, S | 2 |
| Barnas, C | 9 |
| Fabisch, H | 1 |
| Haushofer, M | 1 |
| Sackel, C | 1 |
| König, P | 1 |
| Lingg, A | 1 |
| Platz, T | 1 |
| Rittmannsberger, H | 1 |
| Stuppäck, C | 4 |
| Willeit, M | 2 |
| Zapotoczky, HG | 1 |
| Tauscher, J | 1 |
| Küfferle, B | 1 |
| Asenbaum, S | 1 |
| Brücke, T | 1 |
| Rao, ML | 1 |
| Lin, SK | 1 |
| Lin, HN | 1 |
| Stuppäck, CH | 3 |
| Miller, C | 3 |
| Haring, C | 2 |
| Sperner-Unterweger, B | 2 |
| Hori, M | 1 |
| Suzuki, T | 1 |
| Sasaki, M | 1 |
| Shiraishi, H | 1 |
| Koizumi, J | 1 |
| Klieser, E | 1 |
| Lehmann, E | 1 |
| Tegeler, J | 1 |
| Dieterle, DM | 2 |
| Müller-Spahn, F | 3 |
| Ackenheil, M | 3 |
| Dieterle, D | 1 |
| Harada, T | 2 |
| Otsuki, S | 2 |
| Fujiwara, Y | 2 |
| Hirano, T | 1 |
| Noda, K | 1 |
| Tashiro, Y | 1 |
| Unterweger, B | 5 |
| Hinterhuber, H | 5 |
| von Bardeleben, U | 1 |
| Benkert, O | 1 |
| Holsboer, F | 1 |
| Haug, HJ | 1 |
| Sarai, K | 1 |
| Okada, M | 1 |
| Yamawaki, S | 1 |
| Sato, M | 1 |
| Wake, A | 1 |
| Kashihara, K | 1 |
| Fukuda, K | 1 |
| Kapfhammer, HP | 1 |
| Higashi, Y | 1 |
| Momotani, Y | 1 |
| Suzuki, E | 1 |
| Kaku, T | 1 |
| Stuppaeck, C | 1 |
| Noto, T | 1 |
| Hashimoto, H | 1 |
| Sugae, S | 1 |
| Okamoto, K | 1 |
| Nakao, J | 1 |
| Kamimura, H | 1 |
| Nakajima, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward[NCT00418873] | Phase 4 | 39 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Study was stopped due to difficulty in patient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for zotepine and Dementia Praecox
| Article | Year |
|---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; E | 2001 |
Zotepine: a clinical review.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Dibenzothiepins; Humans; Receptors, A | 2009 |
Zotepine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dibenzothiepins; Humans; Randomized Controlled Trials as Topic; Sch | 2010 |
Safety evaluation of zotepine for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Dibenzothiepins; Female; Humans; Male; Mental Disorders; Randomized Controlled | 2010 |
Zotepine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dibenzothiepins; Humans; Randomized Controlled Trials as Topic; Rem | 2010 |
Clozapine versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Humans; Olanz | 2010 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clozapine; Cognitive Behavioral | 2003 |
Schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Chlorpromazine; Clozapine; Cognitive Behavioral Therapy; Dibenzot | 2005 |
Zotepine for schizophrenia.
Topics: Antipsychotic Agents; Dibenzothiepins; Humans; Psychotic Disorders; Randomized Controlled Trials as | 2006 |
Clozapine: a comparison with other novel antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Double-Blind | 1999 |
Zotepine for schizophrenia.
Topics: Antipsychotic Agents; Dibenzothiepins; Humans; Psychotic Disorders; Schizophrenia | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as T | 2000 |
21 trials available for zotepine and Dementia Praecox
| Article | Year |
|---|---|
Switching from clozapine to zotepine in patients with schizophrenia: a 12-week prospective, randomized, rater blind, and parallel study.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Dibenzothiepins; Dose-Response Relationship, Drug; Dru | 2013 |
An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dibenzothiepins; Female; Hospitalization; Humans; Hyperp | 2013 |
Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chi-Square Distribution; Dibenzothiepins; Dose-Respon | 2004 |
Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Dibenzothiepins; Drug Administration Schedule; Drug Resistance; Female; Humans | 2006 |
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibe | 2007 |
A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dibenzothiepins; Double-Blind Method; F | 1996 |
Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition; Dibenzothiepins; Double-Blind Method; Female; Hum | 1997 |
Placebo revisited.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Dibenzothiepins; Double-Blind Method; Ethic | 2000 |
A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Dibenzothiepins; Dose-Respon | 2000 |
Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method | 2000 |
In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Female; Humans; Iodobenzenes; Male; Neostriatum; Radio | 2001 |
Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Double-Blind Method; Female; Haloperidol; Humans; Male | 2001 |
Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method; Female; Haloperi | 1992 |
[Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, | 1991 |
[Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, Drug; Double-Blind Method; | 1991 |
[Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial].
Topics: Adult; Antipsychotic Agents; Arousal; Attention; Dibenzothiepins; Dose-Response Relationship, Drug; | 1991 |
[Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dibenzothiepins; Female; Humans; Male; Middle Aged; P | 1991 |
[Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Double-Blind Method; Dyskinesia, Drug | 1991 |
Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Dibenzothiepins; Double-Blind Method; Female; | 1989 |
Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Dibenzothiepins; Double-Blind Method; Female; | 1987 |
Zotepine, a neuroleptic drug with a bipolar therapeutic profile.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiepins; Female; Humans; Male; Middle A | 1987 |
41 other studies available for zotepine and Dementia Praecox
| Article | Year |
|---|---|
The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiepins; Female; Haloperidol; Humans; Hyperglycemia; | 2022 |
Age effect of antipsychotic medications on the risk of sudden cardiac death in patients with schizophrenia: A nationwide case-crossover study.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Cross-Over Studies; Death, Sudden, Cardiac; Dibenzot | 2020 |
Zotepine-associated vitamin B12 deficiency and pancytopenia.
Topics: Dibenzothiepins; Humans; Male; Middle Aged; Pancytopenia; Schizophrenia; Vitamin B 12 Deficiency | 2017 |
Zotepine-Associated Hypothermia in a Schizophrenic Inpatient.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Humans; Hypothermia; Male; Schizophrenia | 2017 |
Zotepine-induced spontaneous ejaculation.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Ejaculation; Genital Diseases, Male; Haloperidol; Huma | 2008 |
Valproate and high dosage of zotepine induced acute delirium: a case report.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Delirium; Dibenzothiepins; Dose-Response Relationship | 2012 |
Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Clozapine; Cohort S | 2013 |
Improvement in QTc prolongation induced by zotepine following a switch to perospirone.
Topics: Antipsychotic Agents; Dibenzothiepins; Electrocardiography; Female; Haloperidol; Heart Rate; Humans; | 2012 |
Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Diabetes Complications; Dibenzothiepins; Dopamine; Drug Interact | 2012 |
Zotepine-related myopathy in a patient with schizophrenia.
Topics: Antipsychotic Agents; Dibenzothiepins; Drug Interactions; Humans; Male; Muscular Diseases; Risk Fact | 2013 |
Rifampin-zotepine interaction reduces effectiveness of antipsychotic drugs in a stable schizophrenia patient.
Topics: Antipsychotic Agents; Antitubercular Agents; Dibenzothiepins; Drug Interactions; Female; Humans; Mid | 2012 |
Optimizing the early prediction model for symptomatic remission with short-term treatment for schizophrenia.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dibenzothiepins; Early Diagnosis; Femal | 2012 |
Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients.
Topics: Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiepins; Hostility; Humans; Ola | 2002 |
[Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)?].
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; | 2002 |
Two case studies of hypothermia induced by an increased dosage of zotepine in a combination therapy.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Diazepam; Diben | 2003 |
Treatment of clozapine-associated tardive dyskinesia.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Clozapine; Cross-Over Studies; Dibenzothiepins; | 2008 |
Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Diagnostic and Statis | 2007 |
Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Brief Psychiatric Rating Scale; Dibenzothiepins; Female; Humans; Male; Midd | 1994 |
Three cases of alopecia areata induced by zotepine.
Topics: Adult; Alopecia; Alopecia Areata; Antipsychotic Agents; Autoimmune Diseases; Carbamazepine; Clomipra | 1993 |
Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dibenzothiepins; Drug Interactions; Female; Humans; M | 1994 |
[Therapeutic and adverse effects of zotepine and their relationships with serum kinetics of the drug].
Topics: Adolescent; Adult; Aged; Dibenzothiepins; Drug Evaluation; Female; Humans; Male; Middle Aged; Schizo | 1993 |
[Body weight increase: a side effect of zotepin (Nipolept)?].
Topics: Adult; Antipsychotic Agents; Delusions; Dibenzothiepins; Female; Humans; Male; Middle Aged; Psychoti | 1996 |
[Zotepin--its value and potentials for further development].
Topics: Animals; Antipsychotic Agents; Clozapine; Dibenzothiepins; Disease Models, Animal; Haloperidol; Huma | 1994 |
Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Cross-Sectiona | 1997 |
Plasma concentrations of antipsychotic drugs in psychiatric inpatients.
Topics: Adult; Aged; Alcoholism; Antipsychotic Agents; Benzamides; Butyrophenones; Chromatography, Gas; Chro | 1997 |
Weight gain: side effect of atypical neuroleptics?
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Body Mass Index; C | 1999 |
Novel antipsychotic use in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dibenzothiepins; Drug Administration Sche | 2000 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
Zotepine in the treatment of acute hospitalized schizophrenic episodes.
Topics: Acute Disease; Adult; Antipsychotic Agents; Austria; Dibenzothiepins; Drug Therapy, Combination; Fem | 2001 |
Convulsive seizures in schizophrenic patients induced by zotepine administration.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dibenzothiepins; Dose-Response Relationship, Drug; Dr | 1992 |
Biperiden and piroheptine do not affect the serum level of zotepine, a new antipsychotic drug.
Topics: Adult; Antipsychotic Agents; Biperiden; Dibenzocycloheptenes; Dibenzothiepins; Drug Therapy, Combina | 1990 |
Clinical and neuroendocrine effects of zotepine--a new neuroleptic drug.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Growth Hormone; Hemodynamics; Humans; Hydrocortisone; | 1987 |
Clinical experience with the neuroleptic zotepine--first results.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Electrocardiography; Electroencephalography; Female; H | 1987 |
Profiles of clinical efficacy and pharmacological action of zotepine.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Dibenzothiepins; Humans; Receptors, | 1987 |
Effectivity of zotepine in refractory psychoses: possible relationship between zotepine and non-dopamine psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Dibenzothiepins; Dopamine; Drug Resistance; Female; Halluci | 1987 |
Zotepine in the treatment of negative symptoms in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiepins; Female; Humans; Male; Psychiatric Sta | 1987 |
Low-dose zotepine in the maintenance treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Electrocardiography; Female; Humans; Male; Psychiatric | 1987 |
Results of an open phase II study with zotepine--a new neuroleptic compound.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Drug Evaluation; Female; Humans; Liver; Male; Psychiat | 1987 |
Clinical and EEG studies of zotepine, a thiepine neuroleptic, on schizophrenic patients.
Topics: Antipsychotic Agents; Dibenzothiepins; Electroencephalography; Erythrocytes; Humans; Psychiatric Sta | 1987 |
Treatment of negative symptoms in schizophrenia with zotepine.
Topics: Adult; Antipsychotic Agents; Dibenzothiepins; Female; Humans; Male; Schizophrenia | 1987 |
Hypothermia caused by antipsychotic drugs in a schizophrenic patient.
Topics: Adult; Biperiden; Dibenzothiepins; Drug Therapy, Combination; Fluphenazine; Humans; Hypothermia; Mal | 1987 |